Prostate Specific Antigen News and Research

RSS

Metformin mimics exercise-related metabolic effects in prostate cancer patients

A new study has found that metformin, a widely prescribed diabetes drug, may mimic one of exercise's core biological effects in men with prostate cancer, raising levels of a molecule tied to energy balance and weight control even when patients are inactive.

6 Apr 2026

Human insight and AI advance prostate cancer treatment

Today, many men must choose between life-altering prostate removal or careful long-term monitoring. The EU-funded ROBIOSPY Project offers an intermediate option: precise needle-based diagnostics and targeted therapy powered by AI-driven robotics.

12 Feb 2026

PSMA PET/CT scans may predict prostate cancer recurrence, guide treatment

New research in the February 2026 issue of JNCCN-Journal of the National Comprehensive Cancer Network found that incorporating information from prostate-specific membrane antigen (PSMA) PET/CT scans may be able to predict progression-free survival (PFS) and guide treatment planning in patients with rising prostate-specific antigen (PSA) levels following removal of the prostate.

9 Feb 2026

New liquid biopsy detects early cancers through epigenetic instability

Researchers at the Johns Hopkins Kimmel Cancer Center have developed a novel liquid biopsy approach to identify early-stage cancers by measuring the random variation in DNA methylation patterns, rather than the absolute level of those patterns as in other liquid biopsies.

2 Feb 2026

Pre-surgical medication use grows for pancreatic, gynecologic, and abdominal lining cancers

The second annual report from the National Cancer Database (NCDB) of the American College of Surgeons (ACS) documents a substantial rise in medication treatments, such as chemotherapy, immunotherapy, and hormone therapy, used before surgery to treat many cancers, often allowing less invasive surgery and helping clinicians assess how a patient's cancer responds to medication to guide the most effective treatment options.

22 Jan 2026

PSA-based tool improves decision making for prostate cancer screening and treatment

Prostate cancer is the second-leading cause of cancer death in American men.

16 Jan 2026

New trial aims to improve both survival and quality of life for men with advanced prostate cancer

The Alliance for Clinical Trials in Oncology has launched a randomized phase III clinical trial called RECIPROCAL (Alliance A032304) to explore whether doctors can optimize the timing of targeted radiation therapy to minimize side effects while preserving efficacy in men with advanced prostate cancer.

5 Jan 2026

Study confirms PSA screening improves survival and safety

After 23 years of follow-up, the European Randomized Study of Screening for Prostate Cancer (ERSPC) confirmed a 13% lower prostate cancer mortality with PSA testing and an improved harm–benefit ratio over time. Risk-based screening could sustain mortality gains while reducing overdiagnosis and unnecessary treatment.

30 Oct 2025

Breakthrough combo therapy lowers death risk in recurrent prostate cancer

Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in clinical trials to cut the risk of death by more than 40%.

23 Oct 2025

Many men receive frequent prostate cancer tests without symptoms

Current prostate specific antigen (PSA) testing "may not effectively target testing to those most likely to benefit, raising concerns about overtesting" warn researchers from the University of Oxford in a study of over 10 million men across England published by The BMJ today.

8 Oct 2025

Five-session SBRT reduces side effects in intermediate-risk prostate cancer

For patients with intermediate-risk, localized prostate cancer, radiation therapy delivered in five sessions reduced patient-reported side effects compared to longer courses of radiation, according to results of a large, randomized phase III trial.

29 Sep 2025

Gene expression test identifies prostate cancer patients who benefit from hormone therapy

A new randomized study finds that a lab test that reads tumor genes can identify which patients with recurrent prostate cancer will benefit from adding hormone therapy to radiation after surgery - the first predictive biomarker in this setting.

29 Sep 2025

Primary care providers less likely to recommend PSA testing for Black men

Although Black men die of prostate cancer at twice the rate of the rest of U.S. males, this fact often is not known or considered during appointments with their primary-care clinicians to discuss a common screening test.

13 Sep 2025

Johns Hopkins team develops urine-based test for prostate cancer detection

Researchers at the Johns Hopkins Kimmel Cancer Center, Johns Hopkins All Children's Hospital and four other institutions have devised a novel method to test for prostate cancer using biomarkers present in urine, funded in part by the National Institutes of Health.

9 Sep 2025

Urine test identifies three biomarkers for accurate prostate cancer detection

2 Sep 2025

Prostate cancer rates rise as mortality decline slows in the United States

Today, the American Cancer Society (ACS) released Prostate Cancer Statistics, 2025, a report on current prostate cancer occurrence and outcomes in the United States.

2 Sep 2025

MicroRNA panels show promise for improving prostate cancer diagnosis

Prostate cancer is highly heterogeneous, ranging from slow-growing tumors to aggressive, life-threatening disease.

2 Sep 2025

Rethinking prostate cancer risk in GG1 diagnoses

A new study reveals that some men who are diagnosed with "Grade Group one" (GG1) prostate cancer may actually be at higher risk than biopsy results suggest, according to research led by Weill Cornell Medicine, University Hospitals Cleveland and Case Western University.

31 Jul 2025

New trial offers hope for men with aggressive prostate cancer

Many men with aggressive prostate cancer can experience a high rate of recurrence despite treatment.

30 May 2025

Blood-based biomarkers predict therapy failure in prostate cancer patients

New research has identified specific blood-based biomarkers that can predict the failure of prostate cancer treatment in both hormone-sensitive and castration-resistant patients.

12 May 2025